BR112015006798A2 - vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico - Google Patents

vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico

Info

Publication number
BR112015006798A2
BR112015006798A2 BR112015006798A BR112015006798A BR112015006798A2 BR 112015006798 A2 BR112015006798 A2 BR 112015006798A2 BR 112015006798 A BR112015006798 A BR 112015006798A BR 112015006798 A BR112015006798 A BR 112015006798A BR 112015006798 A2 BR112015006798 A2 BR 112015006798A2
Authority
BR
Brazil
Prior art keywords
mva virus
virus
genome
mva
producing
Prior art date
Application number
BR112015006798A
Other languages
English (en)
Inventor
Jordan Ingo
Sandig Volker
Original Assignee
Probiogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiogen Ag filed Critical Probiogen Ag
Publication of BR112015006798A2 publication Critical patent/BR112015006798A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24061—Methods of inactivation or attenuation
    • C12N2710/24064—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1 / 1 resumo “vã�rus da vacã�nia ankara modificado, genoma, cã‰lula, mã‰todos para cultivar um vã�rus mva, para produzir um vã�rus mva e para produzir um vã�rus mva recombinante, composiã‡ãƒo farmacãšutica, vacina, vã�rus mva ou genoma, e, molã‰cula de ã�cido nucleicoâ€� a presente invenã§ã£o refere-se a um novo vã­rus da vacã­nia ankara modificado (mva). a presente invenã§ã£o tambã©m se refere a um mã©todo para cultivar o dito vã­rus mva e a um mã©todo para produzir o dito vã­rus mva. alã©m disso, a presente invenã§ã£o refere-se a uma composiã§ã£o farmacãªutica compreendendo o dito vã­rus mva e um ou mais excipiente(s), diluente(s), e/ou veã­culo(s) farmacãªutico(s) aceitã¡vel (aceitã¡veis). adicionalmente, a presente invenã§ã£o refere-se a uma vacina compreendendo o dito vã­rus mva. em adiã§ã£o, a presente invenã§ã£o refere-se ao dito vã­rus mva para uso em medicina.
BR112015006798A 2012-09-28 2012-09-28 vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico BR112015006798A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/069256 WO2014048500A1 (en) 2012-09-28 2012-09-28 Novel mva virus and uses thereof

Publications (1)

Publication Number Publication Date
BR112015006798A2 true BR112015006798A2 (pt) 2017-11-21

Family

ID=46982581

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006798A BR112015006798A2 (pt) 2012-09-28 2012-09-28 vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico

Country Status (12)

Country Link
US (1) US9732325B2 (pt)
EP (1) EP2900810B1 (pt)
JP (1) JP2015535687A (pt)
CN (1) CN104812894B (pt)
AU (1) AU2012391162A1 (pt)
BR (1) BR112015006798A2 (pt)
CA (1) CA2885240A1 (pt)
DK (1) DK2900810T3 (pt)
IN (1) IN2015DN02335A (pt)
MX (1) MX2015003687A (pt)
RU (1) RU2015115898A (pt)
WO (1) WO2014048500A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110546252A (zh) * 2017-02-23 2019-12-06 普罗拜奥根股份公司 具有广泛基因组对称的mva相关的新型痘苗病毒载体
CN108371715A (zh) * 2018-01-03 2018-08-07 肖小林 一种病毒的靶向性防治药物
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
JP2021528999A (ja) 2018-07-04 2021-10-28 プロバイオジェン アーゲー エンベロープウイルスの精製方法
WO2023128672A1 (ko) * 2021-12-29 2023-07-06 재단법인 아산사회복지재단 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주
WO2023223183A1 (en) 2022-05-16 2023-11-23 Crispr Therapeutics Ag Picornaviral vectors for gene editing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645456B2 (en) 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
JP5052893B2 (ja) 2003-02-20 2012-10-17 アメリカ合衆国 ポックスベクターにおける新規の挿入部位

Also Published As

Publication number Publication date
US9732325B2 (en) 2017-08-15
CN104812894A (zh) 2015-07-29
JP2015535687A (ja) 2015-12-17
RU2015115898A (ru) 2016-11-20
IN2015DN02335A (pt) 2015-08-28
MX2015003687A (es) 2015-06-15
EP2900810B1 (en) 2019-02-20
DK2900810T3 (en) 2019-04-29
AU2012391162A1 (en) 2015-04-09
CA2885240A1 (en) 2014-04-03
US20150299666A1 (en) 2015-10-22
CN104812894B (zh) 2021-10-22
WO2014048500A1 (en) 2014-04-03
EP2900810A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
BR112015006798A2 (pt) vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
WO2017070626A3 (en) Respiratory virus vaccines
DOP2015000118A (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina
BRPI0712158B8 (pt) processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada
BRPI1015053A2 (pt) partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
EA028928B9 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112013030150A2 (pt) proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma
EA201391515A1 (ru) Инактивированная вакцина вируса денге
WO2005115448A3 (en) Multi plasmid system for the production of influenza virus
WO2006063053A3 (en) Methods of producing influenza vaccine compositions
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
BR112015006763B1 (pt) Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante
CL2015001319A1 (es) Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
MX350932B (es) Formulaciones virales liquidas.
BR112014017242A2 (pt) vlps contendo hpv l2 imunogênico e composições e métodos relacionados
AU2011280259A8 (en) Influenza vaccine
BR112014007474A2 (pt) aumento de rendimento de partícula tipo vírus em plantas
UA113448C2 (xx) Везикули, які містять епідермальний фактор росту і його композиції
BR112014015582A8 (pt) compostos antivirais
BR112018000037A2 (pt) partículas semelhantes a vírus recombinantes usando a proteína gag do vírus da imunodeficiência bovina (vlp de bgag), vacina, vetor plasmidial de transferência para produzir a vlp de bgag, método para fazer a vlp de bgag, método para preparar a vacina
WO2011039180A3 (en) Novel vaccine composition against influenza

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.